滚动资讯
FierceBiotechParabilis preps $413M IPO to fuel desmoid tumor drug into phase 3Lonza NewsStipple Bio Enters Multi-Target License Agreement with Lonza to Advance Precision Oncology ADC Therapies - The Manila TimesLonza NewsStipple Bio与Lonza签署多靶点许可协议,推进精准肿瘤ADC疗法发展——《马尼拉时报》Endpoints NewsParabilis Medicines 计划通过4.13亿美元IPO支持肽类药物管线FierceBiotech刚达成12亿美元交易的Innovent,公布与武田合作的ADC药物三期临床试验成功PharmaVoice众议院法案旨在打击中国生物技术交易PharmaVoice制药公司重押PD-1/VEGF双特异性抗体,但这是否是企业在追逐错误的目标?FierceBiotechMedline因反复出现有毒细菌问题而收到FDA警告信FierceBiotech从商业策略到CAR-T反应,对Cabaletta而言,关键在于‘持久性’。BioWorldFDA clears Shionogi’s Xocova as first COVID-19 prevention pillBruker布鲁克展示扩展的微生物学诊断产品组合 - Investing.comBruker布鲁克在ASM Microbe 2026展示不断扩大微生物学与感染诊断产品线

资讯库

总数 1
主题 Solutions Nonwovens
搜索 --